A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

Trial Profile

A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Atypical Haemolytic Uraemic Syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 27 Sep 2018 Planned number of patients changed from 16 to 23.
    • 08 Feb 2018 According to an Alexion media release, enrollment and dosing is ongoing.
    • 06 Sep 2017 Planned End Date changed from 1 Oct 2020 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top